Ricardo Alonso-Zaldivar, reporter, Washington, D.C., for using cost figures obtained exclusively from Medicare actuaries to describe how the program’s safeguard for consumers with high drug costs had turned into a way for pharmaceutical companies to collect billions of taxpayer dollars for their most pricey products. Analysts worry the development could threaten the future of the Medicare drug program.
Related articles
